Laurentiu "Larry" Pop, M.D., Assistant Professor
Larry received his M.D. and completed a combined residency and fellowship program in medical oncology at Romania’s Craiova University of Medicine and Pharmacy. He completed his postdoctoral research training at the Cancer Immunobiology Center at UT Southwestern, where he was retained as a junior faculty member. He is a diplomate of the American Board of Medical Laboratory Immunology and a certified principal investigator by the Academy of Clinical Research Professionals.
His research interests include investigating tumor escape mechanisms and engineering therapeutic antibodies, immunoconjugates, and vaccines. While affiliated with the Department of Internal Medicine at UT Southwestern, he was involved in a number of clinical trials focused on metabolic disorders. His current research focuses on identifying radiation-induced immune responses in cancer and on finding new avenues for improving radio-immunotherapy.
Subrata Manna, Ph.D., Postdoctoral Researcher
Subrata received both his bachelor’s and master’s degrees in pharmaceutical technology from Jadavpur University in India. He also received a master’s degree and Ph.D. in biological sciences with specialization in tumor immunology from St. John’s University, New York. He completed his first postdoctoral training on estrogen receptor-mTOR signaling in breast cancer from Yeshiva University in New York, then joined UT Southwestern Medical Center as a postdoctoral researcher in September 2016.
Currently, he is interested in radiation-mediated sterile inflammation and neutrophil-mediated innate immune responses leading to cytotoxic T-cell activation in mouse models. In addition, he is working on improving the therapeutic targeting of tumors by the viral capsid-mediated release of the anti-tumor cytotoxic agent doxorubicin coupled with anti-tumor immune response. He is also involved in conducting phase II clinical trials of stereo ablative body radiation therapy (SABR) in patients receiving interleukin-2 (IL-2) therapy or the PD-1 inhibitor Nivolumab in patients with metastatic clear cell renal cell cancer (mRCC) and in patients who were newly diagnosed with renal cell cancer.
Faya Zhang, Ph.D., Postdoctoral Researcher
Faya received his bachelor’s degree in pharmacy from Henan Medical University in China and his master’s degree in medical pharmaceutical sciences from the University of Groningen in the Netherlands. In 2017, he received his Ph.D. in pharmaceutical sciences with a focus on tumor immunology from Washington State University.
Faya joined the Hannan Lab as a postdoctoral researcher, and his current research is focused on how radiation therapy affects antitumor immunity. Specifically, he is studying the mechanism underlying radiation-induced neutrophilic infiltration as a possible link between DNA sensing pathway activation and enhanced anti-tumor immunity.
Erica Salcedo, Research Technician
Erica attended North Central College in Illinois, where she earned her B.A. in biology. She has been at UT Southwestern since August 2018 and started with the Hannan Lab in February 2020.